Cargando…
A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus
We are currently faced with a global infectious disease crisis which has been anticipated for decades. While many promising biotherapeutics are being tested, the search for a small molecule has yet to deliver an approved drug or therapeutic for the Ebola or similar filoviruses that cause haemorrhagi...
Autores principales: | Ekins, Sean, Freundlich, Joel S., Coffee, Megan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304229/ https://www.ncbi.nlm.nih.gov/pubmed/25653841 http://dx.doi.org/10.12688/f1000research.5741.2 |
Ejemplares similares
-
FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015) -
Possible FDA-approved drugs to treat Ebola virus infection
por: Yuan, Shu
Publicado: (2015) -
Finding small molecules for the ‘next Ebola’
por: Ekins, Sean, et al.
Publicado: (2015) -
The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus
por: Jasenosky, Luke D., et al.
Publicado: (2019) -
Ebanga™: The most recent FDA-approved drug for treating Ebola
por: Taki, Elahe, et al.
Publicado: (2023)